Physician profile
Beth R Levy
NPI 1710105606
$704.62
in general payments reported to CMS, 2019-2025
14 companies · $76.68 in 2025
The $76.68 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $202 · 2024: $202 · 2025: $76.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $241.98 | 2022-2023 | Rotarix, Pediarix, Bexsero |
| Corium, LLC | $163.61 | 2022-2025 | Azstarys, Azstarys |
| Kaleo, INC. | $48.27 | 2022-2024 | Auvi-Q |
| Alk-Abello, INC | $33.58 | 2025 | Neffy, Grastek, Odactra |
| Neos Therapeutics, Lp | $32.67 | 2022-2025 | Cotempla Xr-Odt |
| Merck Sharp & Dohme LLC | $29.78 | 2024-2025 | Vaxneuvance, Gardasil 9, Vaqta |
| Tris Pharma INC | $29.40 | 2023-2024 | Dyanavel Xr |
| Abbvie INC. | $25.48 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.60 | 2023 | |
| Seqirus USA INC | $17.44 | 2024 | Flucelvax |
| Pfizer INC. | $16.88 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.28 | 2022 | |
| Covis Pharma Gmbh | $13.68 | 2023 | |
| Aytu Biopharma, INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.